Literature DB >> 11851953

Epidemiology and clinical manifestations of Leishmania donovani infection in two villages in an endemic area in eastern Sudan.

E A G Khalil1, E E Zijlstra, P A Kager, A M El Hassan.   

Abstract

We conducted a longitudinal study in an endemic area for visceral leishmaniasis (VL) in eastern Sudan to compare the epidemiology and clinical spectrum of Leishmania donovani infection in two populations differing in ethnic background and duration of residence in the area. The study took place in two villages from April 1994 to April 1996. In Um-Salala village, which is inhabited by members of the Masaleet tribe, half of the villagers had previous exposure to cutaneous leishmaniasis (Leishmaria major) before moving there. The population of the second village, Mushrau Koka, belong to the Hausa tribe and most were born there. The incidence of VL was 20.4/1000 person-years in 1994/1995 and increased sharply to 38.3/1000 person-years in 1995/1996 in Um-Salala. A rise in the incidence of VL was also observed in Mushrau Koka but with a lower incidence, 3.3/1000 person-years to 4.6/1000 person-years. The incidence rate of confirmed VL reflects only a limited part of the total infection rate which includes various forms of subclinical infection. The ratio of clinical to subclinical infection in Um-Salala was 1.2 : 1 in 1994/1995 compared with 2.6 : 1 in 1995/1996. This ratio was 1 : 11 in 1994/1995 and 1 : 2.5 in 1995/1996 in Mushrau Koka. In both villages the mean age of subclinical cases was higher, but in Mushrau Koka the mean age of subclinical cases also was higher than that of subclinical cases in Um-Salala. The leishmanin skin test (LST) was positive in 56% of individuals in Um-Salala and in 33% in Mushrau Koka. VL only occurred in leishmanin-negative individuals. Post kala-azar dermal leishmaniasis (PKDL) followed in 58% of confirmed VL patients in Um-Salala; the low incidence of VL for Mushrau Koka did not permit to estimate a PKDL rate. The clinical manifestations resulting from exposure to L. donovani range from subclinical infection to VL and PKDL. No firm conclusion as to the difference in incidence of VL between the two villages could be reached but differences in exposure to VL and cutaneous leishmaniasis (CL) as well as other factors such as ethnic background and differences in nutritional status may play a role.

Entities:  

Mesh:

Year:  2002        PMID: 11851953     DOI: 10.1046/j.1365-3156.2002.00832.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  30 in total

1.  [Concerning a case of cutaneous Leishmaniasis with intestinal effects].

Authors:  M Rodríguez Martínez; S Domínguez Palomo; J Mesa Rodríguez; M A Díaz Torres
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

2.  The economic value of a visceral leishmaniasis vaccine in Bihar state, India.

Authors:  Bruce Y Lee; Kristina M Bacon; Mirat Shah; Sara Beth Kitchen; Diana L Connor; Rachel B Slayton
Journal:  Am J Trop Med Hyg       Date:  2012-03       Impact factor: 2.345

3.  Dichotomy of protective cellular immune responses to human visceral leishmaniasis.

Authors:  E A G Khalil; N B Ayed; A M Musa; M E Ibrahim; M M Mukhtar; E E Zijlstra; I M Elhassan; P G Smith; P M Kieny; H W Ghalib; F Zicker; F Modabber; A M Elhassan
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

4.  Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines.

Authors:  Mona E E Elfaki; Eltahir A G Khalil; Anne S De Groot; Ahmed M Musa; Andres Gutierrez; Brima M Younis; Kawthar A M Salih; Ahmed M El-Hassan
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

5.  Genetic and functional evidence implicating DLL1 as the gene that influences susceptibility to visceral leishmaniasis at chromosome 6q27.

Authors:  Michaela Fakiola; E Nancy Miller; Manal Fadl; Hiba S Mohamed; Sarra E Jamieson; Richard W Francis; Heather J Cordell; Christopher S Peacock; Madhuri Raju; Eltahir A Khalil; Ahmed Elhassan; Ahmed M Musa; Fernando Silveira; Jeffrey J Shaw; Shyam Sundar; Selma M B Jeronimo; Muntaser E Ibrahim; Jenefer M Blackwell
Journal:  J Infect Dis       Date:  2011-08-01       Impact factor: 5.226

6.  Cutaneous Infection with Leishmania major Mediates Heterologous Protection against Visceral Infection with Leishmania infantum.

Authors:  Audrey Romano; Nicole A Doria; Jonatan Mendez; David L Sacks; Nathan C Peters
Journal:  J Immunol       Date:  2015-09-14       Impact factor: 5.422

7.  Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia.

Authors:  Michael O Harhay; Piero L Olliaro; Michel Vaillant; François Chappuis; María Angeles Lima; Koert Ritmeijer; Carlos Henrique Costa; Dorcas Lamounier Costa; Suman Rijal; Shyam Sundar; Manica Balasegaram
Journal:  Am J Trop Med Hyg       Date:  2011-04       Impact factor: 2.345

8.  Role of the domestic dog as a reservoir host of Leishmania donovani in eastern Sudan.

Authors:  Mo'awia M Hassan; Omran F Osman; Fathi Ma El-Raba'a; Henk Dfh Schallig; Dia-Eldin A Elnaiem
Journal:  Parasit Vectors       Date:  2009-06-17       Impact factor: 3.876

9.  Interleukin 10 gene polymorphisms and development of post kala-azar dermal leishmaniasis in a selected sudanese population.

Authors:  S Farouk; M A Salih; A M Musa; J M Blackwell; E N Miller; E A Khalil; A M Elhassan; M E Ibrahim; H S Mohamed
Journal:  Public Health Genomics       Date:  2009-12-29       Impact factor: 2.000

Review 10.  A review of the leishmanin skin test: A neglected test for a neglected disease.

Authors:  Jessica Carstens-Kass; Kayla Paulini; Patrick Lypaczewski; Greg Matlashewski
Journal:  PLoS Negl Trop Dis       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.